Immunogenicity of RepliVAX WN, a novel single-cycle West Nile virus vaccine

Michelle H. Nelson, Evandro Winkelmann, Yinghong Ma, Jingya Xia, Peter W. Mason, Nigel Bourne, Gregg N. Milligan

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


We recently reported that immunization with RepliVAX WN, a single-cycle West Nile virus (WNV) vaccine, protected mice against WNV challenge. We have extended these studies by characterizing the RepliVAX WN-elicited antibody and T cell responses. WNV-specific IgG antibody responses comprised predominantly of IgG2c and IgG2b subclasses were detected 8 months after immunization. Vigorous WNV-specific CD4+ and CD8+ T cell responses directed at both structural and nonstructural WNV proteins were detected which were characterized by cytolytic activity and secretion of IFN-γ and TNF-α. Importantly, RepliVAX WN immunization resulted in vigorous CD8+ memory T cell responses detected at 8 months after immunization.

Original languageEnglish (US)
Pages (from-to)174-182
Number of pages9
Issue number2
StatePublished - Dec 16 2010


  • CD8 T cell
  • IgG subclass
  • Single-cycle virus
  • West Nile virus

ASJC Scopus subject areas

  • Molecular Medicine
  • General Immunology and Microbiology
  • General Veterinary
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases


Dive into the research topics of 'Immunogenicity of RepliVAX WN, a novel single-cycle West Nile virus vaccine'. Together they form a unique fingerprint.

Cite this